FDA
-
-
-
-
-
-
-
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
-
-
-
-
-
-
-
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
-
-
-
-
-
-
-
MBX Biosciences to present pipeline updates at JP Morgan conference
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on MBX Biosciences Inc (MBX)
-
-
-
-
-
-
-
MBX Biosciences reports 63% response rate in hypoparathyroidism trial
-
-
-
-
-
-
-
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Microbix Attending & Presenting at Asia Pacific POC 2025
-
327,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

